A Breakthrough in Migraine Diagnosis

February 10, 2025

Recent advances in neuroimaging are bringing us closer to an objective diagnosis of migraines. Korean researchers have published groundbreaking findings showing that migraine sufferers exhibit distinctive structural and functional brain characteristics visible on MRI scans. Their report, A robust multimodal brain MRI-based diagnostic model for migraine: validation across different migraine phases and longitudinal follow-up data, was published last month in the Journal of Headache and Pain.

Currently, migraine diagnosis relies on patients reporting specific symptoms. These include one-sided head pain, moderate to severe intensity, throbbing sensation, nausea, sensitivity to light and noise, and worsening pain with physical activity. A diagnosis typically requires the presence of at least three of these symptoms.

This new research confirms that migraines affect multiple brain networks rather than one area. The study identified three key markers: reduced thickness of certain parts of the brain’s cortex, changes in cortical folding patterns, and abnormalities in the brain’s visual, sensory-motor, and emotional processing networks. These findings represent a significant step toward more precise diagnostic tools for migraines. In the future, we may see a comprehensive diagnostic approach combining clinical symptoms, neuroimaging, and potentially other objective measures to provide more accurate diagnoses and targeted treatments.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe